Business
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Fourth-Quarter and Full-Year 2019 Financial Results and Corporate Update
LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing
About this update from Aldeyra Therapeutics, Inc.
[{"type":"text","content":" LEXINGTON, Mass.--(BUSINESS WIRE)--\nAldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the company will host a conference call on Thursday, March 12, 2020, at 8:00 a.m. ET to discuss financial results for the quarter and year ended December 31, 2019 and provide a corporate update.\n\n\nThe dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID number is 9984588. A live webcast of the conference call will also be available on the investor relations page of the company’s corporate website at https://ir.aldeyra.com.\n\n\nAfter the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.\n\n\nAbout Aldeyra Therapeutics\nAldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are potential first-in-class treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20200305005254/en/\n\nCorporate Contact:\nDavid McMullin\nAldeyra Therapeutics, Inc.\nTel: 781-761-4904 ext. 218\[email protected] \n\n\nInvestor & Media Contact:\nScott Solomon\nSharon Merrill Associates, Inc.\nTel: 617-542-5300\[email protected]\n\nSource: Aldeyra Therapeutics, Inc.","length":3327,"tagName":"div"}]